Details of the Drug Combinations

General Information of This Drug (ID: DMW34B1)

Drug Name

Motixafortide DMW34B1

Synonyms

BL-8040

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Approved	[1]
Acute myeloid leukaemia	2A60	Phase 2	[2]
Myelodysplastic syndrome	2A37	Phase 2	[3]
Pancreatic cancer	2C10	Phase 2	[3]
------------------------------------------------------------------------------------

Drug Type

Peptide

Structure

3D MOL is unavailable

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
BL-8040 + Cytarabine	DCCFUEC	Cytarabine	Acute Myeloid Leukemia	[4]
Nelarabine + BL-8040	DCJXZE3	Nelarabine	T-Acute Lymphoblastic Leukemia	[5]
------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 217159
2	ClinicalTrials.gov (NCT02502968) BL-8040 Addition to Consolidation Therapy in AML Patients.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	ClinicalTrials.gov (NCT01838395) Phase IIa Study Evaluating Safety and Efficacy of BL-8040 in Relapsed/Refractory AML Patients
5	ClinicalTrials.gov (NCT02763384) BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma